Theriva Biologics (TOVX) Total Current Liabilities (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Total Current Liabilities of $10.3 million for Q1 2026, up 25.97% year-over-year from $8.1 million in Q1 2025, and up 2.5% quarter-over-quarter from $10.0 million in Q4 2025.
Theriva Biologics (TOVX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Total Current Liabilities for 17 consecutive years, with $10.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 25.97% year-over-year to $10.3 million; the TTM figure through Mar 2026 stood at $10.3 million (up 25.97% YoY), while the FY2025 annual figure was $10.0 million, up 32.02% from the prior year.
- Total Current Liabilities grew to $10.3 million in Q1 2026 per TOVX's latest filing, from $10.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $12.4 million in Q2 2022 and bottomed at $6.0 million in Q1 2024.
- Historically, Total Current Liabilities has averaged $9.2 million across 5 years, with a median of $8.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 491.94% — and 2024, when it sank 30.28%.
- Theriva Biologics' Total Current Liabilities stood at $7.1 million in 2022, then slipped by 4.56% to $6.7 million in 2023, then increased by 12.57% to $7.6 million in 2024, then soared by 32.02% to $10.0 million in 2025, then gained by 2.5% to $10.3 million in 2026.
- Business Quant data shows TOVX's Total Current Liabilities at $10.3 million in Q1 2026, $10.0 million in Q4 2025, and $11.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 630.93 Mn |
| 10 | Theriva Biologics | 11.13 Mn | 11.13 Mn | - | 12.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.11 Mn |
| Mar 31, 2026 | 10.26 Mn |
| Dec 31, 2025 | 10.01 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 12.39 Mn |
| Mar 31, 2025 | 8.15 Mn |
| Dec 31, 2024 | 7.59 Mn |
| Sep 30, 2024 | 7.32 Mn |
| Jun 30, 2024 | 6.85 Mn |
| Mar 31, 2024 | 6.01 Mn |
| Dec 31, 2023 | 6.74 Mn |
| Sep 30, 2023 | 8.74 Mn |
| Jun 30, 2023 | 9.13 Mn |
| Mar 31, 2023 | 8.62 Mn |
| Dec 31, 2022 | 7.06 Mn |
| Sep 30, 2022 | 12.32 Mn |
| Jun 30, 2022 | 12.42 Mn |
| Mar 31, 2022 | 10.98 Mn |
| Dec 31, 2021 | 3.55 Mn |
| Sep 30, 2021 | 3.16 Mn |